Ask AI

Myelodysplastic Syndromes and Myeloproliferative Neoplasms

Share

Program Content

Activities

  • PulseCast MDS MPNs ASH 2025
    PulseCast: Highlights in MDS/MPNs From the 2025 ASH Annual Meeting
    Podcast Episodes
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 30, 2025

Activities

INCA033989 in ET
Phase I Trial of INCA033989, a First-in-Class Antibody Targeting Mutant Calreticulin: Safety and Efficacy in Essential Thrombocythemia
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2025

IMerge Post Hoc Analysis
IMerge Post Hoc Analysis: Treatment-Emergent Cytopenias and Response With Imetelstat in Patients With Lower-Risk MDS
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2025

VERONA Subgroup Analyses
VERONA: Subgroup Analyses of Venetoclax or Placebo Combined With Azacitidine in Treatment-Naive Higher-Risk MDS
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2025

INCA033989 in MF
Preliminary Results From 2 Phase I Trials Exploring the Mutant Calreticulin-Specific mAb INCA033989 ± Ruxolitinib in Patients With MF
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2025

MANIFEST 2 96 Wk Update
MANIFEST-2 96-Wk Update: Ruxolitinib + Pelabresib or Placebo in Patients With JAK Inhibitor–Naive MF
Case Challenge
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2025

Reduced Duration HMA in LR MDS
Randomized Phase II Trial of Reduced Treatment Durations With Hypomethylating Agents in Lower-Risk MDS
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with Smart Patients.

Supporters

Supported by educational grants from AstraZeneca, BeOne Medicines, Genentech, Geron Corporation, Incyte, Johnson & Johnson, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

BeOne Medicines

Genentech

Geron Corporation

Incyte

Johnson & Johnson

Lilly

Novartis Pharmaceuticals Corporation

Partners

Smart Patients

ProCE Banner